SymbioCellTech

Executive Summary

SymbioCellTech is a San Diego-based biotechnology company developing Neo-Islets, a novel cell therapy designed to provide a functional cure for Type 1 and Type 2 diabetes. The therapy combines allogeneic pancreatic beta cells with mesenchymal stem cells to create a durable, physiologically regulated insulin source that functions without immunosuppression. This innovative approach aims to address the limitations of existing therapies, such as the need for lifelong immunosuppression in islet transplantation and the challenges of insulin injection or pump therapies. SymbioCellTech's technology has the potential to significantly improve the quality of life for millions of diabetes patients by restoring natural insulin production and glycemic control. The company is privately held and, as of early 2026, has not disclosed detailed financial or pipeline milestones. However, its unique value proposition positions it as a compelling player in the cell and gene therapy space, albeit at an early development stage.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Neo-Islets in Type 1 Diabetes40% success
• Q4 2026Phase 1/2 Clinical Trial Initiation35% success
• Q1 2027Strategic Partnership or Licensing Deal50% success